PMC:7600245 / 17485-17743 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T64","span":{"begin":3,"end":11},"obj":"Disease"},{"id":"T65","span":{"begin":188,"end":199},"obj":"Disease"},{"id":"T66","span":{"begin":188,"end":197},"obj":"Disease"},{"id":"T67","span":{"begin":212,"end":221},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0005344"},{"id":"A66","pred":"mondo_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T159","span":{"begin":99,"end":100},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T160","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T161","span":{"begin":200,"end":205},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T186","span":{"begin":101,"end":110},"obj":"Chemical"},{"id":"T187","span":{"begin":111,"end":121},"obj":"Chemical"}],"attributes":[{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_17748"},{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":188,"end":197},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}

{"project":"LitCovid-sentences","denotations":[{"id":"T129","span":{"begin":59,"end":63},"obj":"Sentence"},{"id":"T130","span":{"begin":64,"end":95},"obj":"Sentence"},{"id":"T131","span":{"begin":96,"end":227},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}

{"project":"LitCovid-PubTator","denotations":[{"id":"420","span":{"begin":12,"end":20},"obj":"Species"},{"id":"434","span":{"begin":3,"end":11},"obj":"Disease"},{"id":"439","span":{"begin":64,"end":73},"obj":"Chemical"},{"id":"440","span":{"begin":75,"end":82},"obj":"Chemical"},{"id":"441","span":{"begin":87,"end":94},"obj":"Chemical"},{"id":"451","span":{"begin":101,"end":121},"obj":"Chemical"},{"id":"455","span":{"begin":188,"end":221},"obj":"Disease"}],"attributes":[{"id":"A420","pred":"tao:has_database_id","subj":"420","obj":"Tax:9606"},{"id":"A434","pred":"tao:has_database_id","subj":"434","obj":"MESH:C000657245"},{"id":"A439","pred":"tao:has_database_id","subj":"439","obj":"MESH:C034935"},{"id":"A440","pred":"tao:has_database_id","subj":"440","obj":"MESH:C034935"},{"id":"A441","pred":"tao:has_database_id","subj":"441","obj":"MESH:C034935"},{"id":"A455","pred":"tao:has_database_id","subj":"455","obj":"MESH:D006509"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"in COVID-19 patients with mild to moderate symptoms [59].\n\n2.4. Clevudine (Levovir and Revovir)\nIt a thymidine nucleoside analog (Figure 3) that was approved in Korea for the treatment of hepatitis B virus (HBV) infection [60]. Similar to previous agents, it"}